Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fuji
Cipla
Healthtrust
Teva
Merck
Cantor Fitzgerald
Argus Health
Queensland Health

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALITRETINOIN

« Back to Dashboard

Clinical Trials for Alitretinoin

Trial ID Title Status Sponsor Phase Summary
NCT00002188 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed Ligand Pharmaceuticals Phase 2 The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
NCT00002188 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed Anderson Clinical Research Phase 2 The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
NCT00002439 A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma Completed Ligand Pharmaceuticals N/A The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .
NCT00002439 A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma Completed Anderson Clinical Research N/A The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .
NCT00124436 Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis Completed Basilea Pharmaceutica Phase 3 Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to >75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.
NCT00124475 Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis Completed Basilea Pharmaceutica Phase 3 The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.
NCT00309621 Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis Completed Basilea Pharmaceutica Phase 3 Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Alitretinoin

Condition Name

Condition Name for Alitretinoin
Intervention Trials
Hand Dermatoses 3
Eczema 2
HIV Infections 2
Sarcoma, Kaposi 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Alitretinoin
Intervention Trials
Eczema 5
Dermatitis 4
Skin Diseases 3
Hand Dermatoses 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Alitretinoin

Trials by Country

Trials by Country for Alitretinoin
Location Trials
United States 32
Germany 11
Canada 6
Netherlands 3
Denmark 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Alitretinoin
Location Trials
California 1
New Hampshire 1
District of Columbia 1
Florida 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Alitretinoin

Clinical Trial Phase

Clinical Trial Phase for Alitretinoin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Alitretinoin
Clinical Trial Phase Trials
Completed 11
Recruiting 3
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Alitretinoin

Sponsor Name

Sponsor Name for Alitretinoin
Sponsor Trials
Basilea Pharmaceutica 6
Ligand Pharmaceuticals 2
University Hospital, Gentofte, Copenhagen 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Alitretinoin
Sponsor Trials
Industry 14
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Fuji
Johnson and Johnson
US Department of Justice
Moodys
Boehringer Ingelheim
Baxter
QuintilesIMS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.